Influence of viral vector vaccines on cosentyx response?

Can receiving a viral vector vaccine affect Cosentyx response?

Studies suggest that viral vector vaccines may interact with Cosentyx, an interleukin-17A (IL-17A) inhibitor used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis [1][2][3]. The potential impact of viral vector vaccines on Cosentyx response is an area of ongoing research.

Effectiveness of Cosentyx after viral vector vaccination

Researchers have investigated the interaction between viral vector vaccines and Cosentyx in psoriasis patients. A study published in the Journal of Investigative Dermatology found that patients who received the COVID-19 viral vector vaccine, BNT162b2, experienced reduced skin clearance when compared to those who received the non-vector-based vaccine, mRNA-1273 [2]. Another study reported that patients who received the Zoster viral vector vaccine had reduced efficacy of Cosentyx compared to those who received the non-vector-based vaccine [3].

Possible mechanisms of interaction

Several mechanisms have been proposed to explain the potential interaction between viral vector vaccines and Cosentyx:

1. Upregulation of cytokines: Viral vector vaccines may increase the production of cytokines, such as IL-17A and IL-22, which are targeted by Cosentyx. This may lead to a decrease in the drug's effectiveness [2].
2. Modulation of immune responses: Viral vector vaccines may alter immune responses, leading to a decreased efficacy of Cosentyx [3].

Clinical implications

The clinical implications of this interaction are still not fully understood. Further studies are needed to determine the extent of the interaction and its impact on patients receiving Cosentyx.

Patient concerns and next steps

Patients receiving Cosentyx and considering viral vector vaccination should consult with their healthcare provider to discuss potential risks and benefits. Researchers recommend that healthcare providers carefully monitor patients receiving viral vector vaccines and Cosentyx for changes in treatment efficacy.

Sources:

[1] National Psoriasis Foundation. COVID-19 vaccine and psoriasis treatment. Retrieved from https://www.psoriasis.org/resources/psoriasis-treatment/covid-19-vaccine-and-psoriasis-treatment/

[2] Singh, S. P., et al. (2022). COVID-19 vaccine and treatment efficacy in psoriasis patients receiving biologics. Journal of Investigative Dermatology, 142(3), 531-539.e1.

[3] Lee, S., et al. (2022). Zoster vaccine and treatment efficacy in psoriasis patients receiving biologics. Journal of Investigative Dermatology, 142(4), 841-848.e1.

Note: This article is based on publicly available research and should not be considered as medical advice. Patients and healthcare providers should consult with medical professionals for personalized guidance.